Skip to main content
    M

    Molecular Partners AG ADR (MOLN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.67
    -0.27 (-9.18%)

    Market Cap: $112.71M

    Last updated: Nov 17, 2026 at 10:12 AM ET

    Molecular Partners AG ADR (MOLN) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Molecular Partners AG ADR are Pmv Pharmaceuticals (PMVP), Invivyd (IVVD) and MacroGenics (MGNX). By market cap, Molecular Partners AG ADR ranks 10th of the 13 companies on this page; Invivyd (IVVD) is the largest at $171.58M.

    Peer Comparison

    MOLN's revenue growth of -100.0% is below the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Molecular Partners AG ADR (MOLN)$112.71MN/AN/A0.0%N/A-100.0%0.00%
    Pmv Pharmaceuticals Inc (PMVP)$95.93MN/AN/A0.0%N/A0.0%0.00%
    Invivyd Inc. (IVVD)$171.58MN/A2.9x-183.9%N/A21.2%0.00%
    MacroGenics Inc (MGNX)$140.60MN/A1.2x-36.6%-108.7%-64.8%0.00%
    PDS Biotechnology Corp (PDSB)$107.07MN/AN/A0.0%-149.8%0.0%0.00%
    LENZ Therapeutics Inc (LENZ)$129.77MN/A9.7x0.0%N/A-72.9%0.00%
    Innate Pharma (IPHA)$154.15MN/A17.6x0.0%489.8%16.5%0.00%
    Minerva Neurosciences Inc (NERV)$114.62MN/AN/A0.0%N/A0.0%0.00%
    Zentalis Pharmaceuticals Llc (ZNTL)$167.05MN/AN/A0.0%N/A0.0%0.00%
    PolyPid (PYPD)$132.25MN/AN/A0.0%N/A0.0%0.00%
    Compass Therapeutics Inc. (CMPX)$139.35MN/AN/A0.0%N/A0.0%0.00%
    Upstream Bio, Inc. (UPB)$152.38MN/A41.0x0.0%N/A-42.2%0.00%
    Tiziana Life Sciences Ltd (TLSA)$72.53MN/AN/A0.0%N/A0.0%0.00%
    Peer median$135.80MN/A9.7x0.0%-108.7%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Molecular Partners AG ADR, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Pmv Pharmaceuticals Inc (PMVP)
    PMV Pharmaceuticals, Inc., a precision oncology company, is dedicated to the discovery and development of small molecule tumor agnostic therapies for p53...
    PMVP competitors
    Invivyd Inc. (IVVD)
    Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery...
    IVVD competitors
    MacroGenics Inc (MGNX)
    MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States.
    MGNX competitors
    PDS Biotechnology Corp (PDSB)
    PDS Biotechnology Corporation, a clinical-phase biopharmaceutical company, is focused on developing multifunctional cancer immunotherapies.
    PDSB competitors
    LENZ Therapeutics Inc (LENZ)
    LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders...
    LENZ competitors
    Innate Pharma (IPHA)
    Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France...
    Minerva Neurosciences Inc (NERV)
    Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of candidate products...
    NERV competitors
    Zentalis Pharmaceuticals Llc (ZNTL)
    Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment...
    ZNTL competitors
    PolyPid (PYPD)
    PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX)...
    PYPD competitors
    Compass Therapeutics Inc. (CMPX)
    Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple...
    CMPX competitors
    Upstream Bio, Inc. (UPB)
    Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders.
    UPB competitors
    Tiziana Life Sciences Ltd (TLSA)
    Tiziana Life Sciences Plc, a clinical-stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat...

    Frequently Asked Questions About MOLN

    Who are Molecular Partners AG ADR's main competitors?

    The companies most similar to Molecular Partners AG ADR include Pmv Pharmaceuticals (PMVP), Invivyd (IVVD), MacroGenics (MGNX), PDS Biotechnology (PDSB) and LENZ Therapeutics (LENZ), listed from the closest match.

    Who is Molecular Partners AG ADR's biggest competitor?

    Invivyd (IVVD) is the largest of the similar companies at $171.58M; Pmv Pharmaceuticals (PMVP) is the closest match by business profile, size, sector and industry.

    How does MOLN stock compare with its competitors?

    MOLN's net margin is 0.0% against a peer median of 0.0%.

    Which of Molecular Partners AG ADR's competitors pays a higher dividend?

    Molecular Partners AG ADR pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Molecular Partners AG ADR bigger than its competitors?

    No. Molecular Partners AG ADR is 10th by market cap among the 13 companies on this page; the largest is Invivyd (IVVD) at $171.58M.